U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C65H85N17O12
Molecular Weight 1296.4796
Optical Activity UNSPECIFIED
Defined Stereocenters 9 / 9
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of AVORELIN

SMILES

CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=C(C)NC3=C2C=CC=C3)NC(=O)[C@H](CC4=CC=C(O)C=C4)NC(=O)[C@H](CO)NC(=O)[C@H](CC5=CNC6=C5C=CC=C6)NC(=O)[C@H](CC7=CN=CN7)NC(=O)[C@@H]8CCC(=O)N8

InChI

InChIKey=HJNZCKLMRAOTMA-BRBGIFQRSA-N
InChI=1S/C65H85N17O12/c1-5-69-63(93)54-17-11-25-82(54)64(94)47(16-10-24-70-65(66)67)75-57(87)48(26-35(2)3)76-61(91)52(30-43-36(4)73-45-15-9-7-13-42(43)45)80-58(88)49(27-37-18-20-40(84)21-19-37)77-62(92)53(33-83)81-59(89)50(28-38-31-71-44-14-8-6-12-41(38)44)78-60(90)51(29-39-32-68-34-72-39)79-56(86)46-22-23-55(85)74-46/h6-9,12-15,18-21,31-32,34-35,46-54,71,73,83-84H,5,10-11,16-17,22-30,33H2,1-4H3,(H,68,72)(H,69,93)(H,74,85)(H,75,87)(H,76,91)(H,77,92)(H,78,90)(H,79,86)(H,80,88)(H,81,89)(H4,66,67,70)/t46-,47-,48-,49-,50-,51-,52+,53-,54-/m0/s1

HIDE SMILES / InChI

Molecular Formula C65H85N17O12
Molecular Weight 1296.4796
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 9 / 9
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including: DOI: 10.1023/A:1008898216113 | https://www.ncbi.nlm.nih.gov/pubmed/16939388

Avorelin is a superagonist of natural luteinizing-hormone-releasing-hormone. Avorelin has been formulated in high molecular weight polylactic glycolic acid to afford protracted and continuous release of the peptide from subcutaneous implants. Avorelin has been in phase II clinical trials by Mediolanum for the treatment of prostate cancer, breast cancer and endometriosis. However, this research has been discontinued. Adverse events mainly related to androgen suppression (hot flushes, decreased libido and impotence) or the nature of the disease (skeletal pain).

Approval Year

Targets

Targets

Conditions
PubMed

PubMed

TitleDatePubMed
Pharmacodynamics of a long acting depot preparation of avorelin in patients with prostate cancer. Avorelin Study Group.
1999-12
Manipulation of postnatal testosterone levels affects phallic and clitoral development in infant rhesus monkeys.
1999-04
Investigation of the role of postnatal testosterone in the expression of sex differences in behavior in infant rhesus macaques (Macaca mulatta).
1999-04
Patents

Sample Use Guides

In Vivo Use Guide
Sources: DOI: 10.1023/A:1008898216113
10 or 15 mg implants
Route of Administration: Other
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Mon Mar 31 19:21:34 GMT 2025
Edited
by admin
on Mon Mar 31 19:21:34 GMT 2025
Record UNII
FSB5837STQ
Record Status FAILED
Record Version
  • Download
Name Type Language
EP-23904
Preferred Name English
AVORELIN
INN   WHO-DD  
INN  
Official Name English
METERELIN
Common Name English
1-9-LUTEINIZING HORMONE-RELEASING FACTOR (SWINE), 6-(2-METHYL-D-TRYPTOPHAN)-9-(N-ETHYL-L-PROLINAMIDE)-
Common Name English
avorelin [INN]
Common Name English
5-OXO-L-PROLYL-L-HISTIDYL-L-TRYPTOPHYL-L-SERYL-L-TYROSYL-2-METHYL-D-TRYPTOPHYL-L-LEUCYL-L-ARGINYL-N-ETHYL-L-PROLINAMIDE
Common Name English
MF-6001
Code English
Avorelin [WHO-DD]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C1910
Created by admin on Mon Mar 31 19:21:34 GMT 2025 , Edited by admin on Mon Mar 31 19:21:34 GMT 2025
Code System Code Type Description
EPA CompTox
DTXSID401339206
Created by admin on Mon Mar 31 19:21:34 GMT 2025 , Edited by admin on Mon Mar 31 19:21:34 GMT 2025
PRIMARY
PUBCHEM
25074428
Created by admin on Mon Mar 31 19:21:34 GMT 2025 , Edited by admin on Mon Mar 31 19:21:34 GMT 2025
PRIMARY
FDA UNII
FSB5837STQ
Created by admin on Mon Mar 31 19:21:34 GMT 2025 , Edited by admin on Mon Mar 31 19:21:34 GMT 2025
PRIMARY
EVMPD
SUB05618MIG
Created by admin on Mon Mar 31 19:21:34 GMT 2025 , Edited by admin on Mon Mar 31 19:21:34 GMT 2025
PRIMARY
CAS
140703-49-7
Created by admin on Mon Mar 31 19:21:34 GMT 2025 , Edited by admin on Mon Mar 31 19:21:34 GMT 2025
PRIMARY
SMS_ID
100000086902
Created by admin on Mon Mar 31 19:21:34 GMT 2025 , Edited by admin on Mon Mar 31 19:21:34 GMT 2025
PRIMARY
ChEMBL
CHEMBL2103984
Created by admin on Mon Mar 31 19:21:34 GMT 2025 , Edited by admin on Mon Mar 31 19:21:34 GMT 2025
PRIMARY
NCI_THESAURUS
C99154
Created by admin on Mon Mar 31 19:21:34 GMT 2025 , Edited by admin on Mon Mar 31 19:21:34 GMT 2025
PRIMARY
INN
7080
Created by admin on Mon Mar 31 19:21:34 GMT 2025 , Edited by admin on Mon Mar 31 19:21:34 GMT 2025
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
TARGET -> AGONIST
Related Record Type Details
ACTIVE MOIETY